Reuters logo
BRIEF-Protagonist Therapeutics says will be responsible for conduct of Phase 1 clinical trial for PTG-200
May 30, 2017 / 11:41 AM / 4 months ago

BRIEF-Protagonist Therapeutics says will be responsible for conduct of Phase 1 clinical trial for PTG-200

May 30 (Reuters) - Protagonist Therapeutics Inc

* Protagonist Therapeutics Inc says co will be responsible, at its own expense, for conduct of Phase 1 clinical trial for PTG-200 - SEC filing

* Protagonist Therapeutics Inc - Janssen will be responsible for conduct of a phase 2 clinical trial for ptg-200 in CD

* Protagonist therapeutics -development costs for phase 2 clinical trial to be shared between parties on an 80 percent Janssen and 20 percent protagonist basis

* Protagonist Therapeutics - with funding from this collaboration, co believes it has financial resources to fund all activities until middle of 2019 Source text: (bit.ly/2rQTmSS) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below